FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD ...

Four couples who’ve made lasting impacts on charitable causes both here and across the nation have been named Grand Marshals ...

The best fresh dog food brands offer subscriptions, convenient delivery, and nutritious recipes. Our top tested picks meet ...

Energy Star, the program that helps guide consumers to more energy-efficient appliances and electronics, has survived the ...

In addition to the buying opportunities throughout the show, the Dealer Market also offers attendees a front-row seat to the retail innovations that are helping drive profitability, overcome ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript February 5, 2026 Arrowhead Pharmaceuticals, ...

Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, ...